Biotech leaders discussed the value of medical innovation and public perception of drug development at the Georgia BIO Summit on September 28 in Atlanta. During a panel discussion, James Greenwood, president and CEO, Biotechnology Innovation Organization (BIO), said it's important to connect the dots for non-scientists and to remind them that innovation is responsible for improved health outcomes. He added that short-sighted policies, outdated laws and regulations can stifle innovation and delay new treatments and cures for patients. Gillian Cannon, president of North American Operations, UCB, Inc., said that the various stakeholders across the health spectrum need to work together to define value and make sure it is optimized for patients. Care coordination is key, she said, to driving value for patients.
Research!America president and CEO Mary Woolley said a new survey, supported by the Georgia Research Alliance and other partners, shows that a majority of Georgians say it is important for the state to lead in medical research and science and technology but noted that half of respondents do not believe we are making enough progress in developing new medicines. Many Georgians attributed lack of progress in medical research to the following: too many regulatory barriers (56%), not enough researchers (48%), not spending enough money (46%) and an R&D tax burden that is too high (45%). “Georgians understand that university and private sector research must receive adequate support from both the federal and state governments to help find solutions to what ails us,” Woolley said. To view the survey results, click here.